1 Department of Respiratory Medicine, Jinling Hospital, Nanjing University, School of Medicine, Nanjing 210002, China ; 2 Southern Medical University, Guangzhou 510515, China.
J Thorac Dis. 2014 Jun;6(6):803-9. doi: 10.3978/j.issn.2072-1439.2014.05.02.
A number of studies have investigated the relationship between fibroblast growth factor receptor1 (FGFR1) gene copy number and survival in non-small cell lung cancer (NSCLC) patients. However, conclusions reported by different parties seem to be inconsistent, especially regarding the differences among different histopathologic subtypes. To derive a more precise estimate of the prognostic significance of FGFR1 gene copy number, we have reviewed published studies and carried out a meta-analysis.
The meta-analysis was conducted in accordance with PRISMA guidelines. The required data for estimation of individual hazard ratios (HRs) for survival were extracted from the publications and an overall HR was calculated.
We identified 6 eligible studies, all dealing with NSCLC. The global quality score ranged 32.5-80%, with a median of 53.33%. For FGFR1 amplification in three studies including differed according to histological type, the overall RR was 0.86 which 95% confidence interval (CI) was 0.75 to 0.99 and P value was 0.048. Combined HR for the six evaluable studies was 1.17 (95% CI: 0.95 to 1.43). In the subgroup of squamous cell lung cancer (SQCC), the combined HR was 1.24 (95% CI: 0.89 to 1.73). For the Asian populations' studies, the combined HR was 1.67 (95% CI: 1.1 to 2.52).
FGFR1 amplification significantly was more frequent in SQCC. FGFR1 was not associated with poorer survival in patients with NSCLC. Furthermore studies will be needed in terms of survival implications.
多项研究调查了成纤维细胞生长因子受体 1（FGFR1）基因拷贝数与非小细胞肺癌（NSCLC）患者生存之间的关系。然而，不同研究组的结论似乎不一致，尤其是在不同组织病理学亚型之间。为了更准确地评估 FGFR1 基因拷贝数的预后意义，我们对已发表的研究进行了回顾和荟萃分析。
荟萃分析符合 PRISMA 指南进行。从出版物中提取了用于估计个体生存风险比（HRs）的所需数据，并计算了总体 HR。
我们确定了 6 项符合条件的研究，均涉及 NSCLC。全球质量评分范围为 32.5-80%，中位数为 53.33%。对于 3 项涉及根据组织学类型不同的 FGFR1 扩增研究，整体 RR 为 0.86，95%置信区间（CI）为 0.75 至 0.99，P 值为 0.048。对 6 项可评估研究的合并 HR 为 1.17（95%CI：0.95 至 1.43）。在鳞状细胞肺癌（SQCC）亚组中，合并 HR 为 1.24（95%CI：0.89 至 1.73）。对于亚洲人群的研究，合并 HR 为 1.67（95%CI：1.1 至 2.52）。
FGFR1 扩增在 SQCC 中更为常见。FGFR1 与 NSCLC 患者的生存较差无关。此外，还需要进行关于生存影响的研究。
